All News

Prof. Wittmann discusses the current tx for CLE using a stepwise approach. Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ

Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow Summary below. https://t.co/QC0Li38eh6

https://x.com/bella_mehta/status/2062477449078706665/photo/1

After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow

#EULAR2026 POS0729 Longer-term data of autologous CD19 CAR-T appear favourable in #SLE. 4-year data of the initial 8 patients treated at Erlangen remained in GC- and IS-free remission. Infection profile declined over time apart from some blips during COVID pandemic @RheumNow https://t.co/QZMxA2CK33

https://x.com/Yuz6Yusof/status/2062475626238369985/photo/1

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

https://x.com/DrMiniDey/status/2062474451246318046/photo/1

#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX

https://x.com/Yuz6Yusof/status/2062471735811723465/photo/1

#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti

https://x.com/Yuz6Yusof/status/2062465291452330038/photo/1

What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC

Leflunomide is not associated w/ incident or progressive ILD Longitudinal CT Study 184 RA pts LEF exposure inversely asso w/ new lung involvement #POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf

Brand new #MOA in #Rx of #skin #lupus! #Litifilimab - acts on #dendritic cells ⬇️decreases #chemokines & #cytokines +RCT in #cutaneous features of lupus N=93 2:1 randomized #liti v #pbo Rapid onset <4wks HIgh #CLASI response #EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU

SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

https://x.com/Yuz6Yusof/status/2062458622936760812/photo/1

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

https://x.com/RHEUMarampa/status/2062458264655134775/photo/1

TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205

MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

https://x.com/AurelieRheumo/status/2062456064033906821/photo/1

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

#OP0225 at #EULAR2026: In this nationwide French cohort, patients with IMIDs had nearly 2x risk of HPV-related cancers or severe dysplasia versus matched controls. Risk was particularly increased in SLE, reinforcing the importance of HPV vaccination and screening. @RheumNow

#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a

https://x.com/Yuz6Yusof/status/2062453706897981707/photo/1

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

https://x.com/Yuz6Yusof/status/2062469410732790078/photo/1

Topics

All News

Do you get our email newsletter?